[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

855-907-3286

Email address

Clinical.Trials@bms.com

Condition

Lupus Erythematosus, Systemic

Treatment type

Interventional

Investigational product

CC-97540

Phase

Phase 1

Sponsor

Bristol-Myers Squibb

ClinicalTrials.gov identifier

NCT05869955

Study number

CA061-1001

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory Systemic Lupus Erythematosus (SLE).

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

  1. Diagnosis of SLE defined as follows:
  2. Fulfilling the 2019 ACR/EULAR classification criteria of SLE
  3. Presence of anti-dsDNA, anti-histone, anti-chromatin, or anti-Sm antibodies
  4. SLE disease activity
  5. Active disease at screening, defined as ≥ 1 major organ system with a BILAG A score (excluding musculoskeletal, mucocutaneous, and/or constitutional organ system)
  6. ii) Inadequate response to glucocorticoids and to at least 2 of the following treatments, used for at least 3 months each: cyclophosphamide, mycophenolic acid or its derivatives, belimumab, azathioprine, anifrolumab, methotrexate, rituximab, obinutuzumab, cyclosporin, tacrolimus or voclosporin. i) Insufficient response is defined as lack of response, insufficient response or lack of sustained response to appropriate doses. Intolerance is not considered insufficient response ii) Methotrexate and azathioprine use will count as 1 for the purposes of the number of failed treatments.
Exclusion criteria

  1. Diagnosis of drug-induced SLE rather than idiopathic SLE
  2. Other systemic autoimmune diseases (eg, multiple sclerosis, psoriasis, inflammatory bowel disease, etc) are excluded. Participants with type I autoimmune diabetes mellitus, thyroid autoimmune disease, Celiac disease, or secondary Sjögren's syndrome are not excluded
  3. SLE overlap syndromes including, but not limited to, rheumatoid arthritis, scleroderma, and mixed connective tissue disease, are excluded
  4. Recent or present clinically significant CNS pathology Other protocol-defined Inclusion/Exclusion criteria apply.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site